Zheng Yujiao, Jin De, Lin Jiaran, Zhang Yuehong, Tian Jiaxing, Lian Fengmei, Tong Xiaolin
Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Front Med (Lausanne). 2021 Feb 22;8:617659. doi: 10.3389/fmed.2021.617659. eCollection 2021.
Traditional Chinese medicine (TCM) has played a significant role in the treatment of coronavirus disease 2019 (COVID-19) in Wuhan City. During the epidemic, Academician Tong Xiaolin suggested a close association of COVID-19 with cold-dampness, an etiological factor in TCM, by summarizing the characteristics of the COVID-19 patients in Wuhan. and the theory of Cold-dampness Plague was proposed. Based on the Cold-dampness Plague theory, a series of TCM drugs, such as Huoxiang Zhengqi Dropping Pills, Lianhua Qingwen Granules Hanshiyi Formula, and Tongzhi Granule were developed for the different stages, namely mild, moderate, severe, recovery, of the COVID-19. In addition, clinical evidences were obtained through randomized clinical trials or retrospective cohort studies. The Anti-SARS-CoV-2 mechanism of the TCM prescriptions were then summarized from the four aspects: targeting the ACE2 and 3CLPro, targeting cytokines, targeting acute immune responses to SARS-CoV-2, and targeting pulmonary fibrosis. Despite the clinical efficacy and therapeutic pharmacology speculation, more studies such as large-scale randomized clinical trials, cell and animal experiments are needed to further verify the theory of the Cold-dampness Plague in COVID-19 patients.
中医在武汉市新型冠状病毒肺炎(COVID-19)的治疗中发挥了重要作用。疫情期间,仝小林院士通过总结武汉市COVID-19患者的特点,提出COVID-19与中医病因学中的寒湿密切相关,并提出了寒湿疫理论。基于寒湿疫理论,针对COVID-19的不同阶段,即轻症、普通型、重型、恢复期,研发了一系列中药,如藿香正气滴丸、连花清瘟颗粒、寒湿疫方、通治方颗粒等。此外,还通过随机临床试验或回顾性队列研究获得了临床证据。然后从靶向血管紧张素转换酶2(ACE2)和3C样蛋白酶(3CLPro)、靶向细胞因子、靶向对SARS-CoV-2的急性免疫反应以及靶向肺纤维化四个方面总结了中药方剂抗SARS-CoV-2的机制。尽管有临床疗效和治疗药理学推测,但仍需要更多的研究,如大规模随机临床试验、细胞和动物实验,以进一步验证COVID-19患者寒湿疫理论。